Bristol Myers Ends Clinical Development of ORM-6151
Bristol Myers Squibb discontinued the Phase I program for ORM-6151, also known as BMS-986497, after reviewing clinical data in AML and MDS. The CD33-targeted degrader-antibody conjugate carried a GSPT1 molecular-glue payload and was the…
